SCHEMBL19299696

SCHEMBL19299696

O=C(NC(=S)NNC(=O)c1ccco1)c1ccc(F)c(F)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.68
KDM4E B2RXH2 9/20 0.67
KMT2A Q03164 8/20 0.67
MAPT P10636 8/20 0.67
MEN1 O00255 6/20 0.67
LMNA P02545 5/20 0.60
CRHBP P24387 1/20 0.60
CRHR2 Q13324 1/20 0.60
HTT P42858 6/20 0.57
CYP2C9 P11712 3/20 0.57
RAB9A P51151 2/20 0.57
RECQL P46063 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
NPC1 O15118 1/20 0.57
ALDH1A1 P00352 6/20 0.56
HPGD P15428 2/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19299695 0.81 KDM4E (1.00) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL19299372 0.78 KMT2A (1.00) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL19294519 0.77 GAA (0.67) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL19299516 0.75 KDM4E (1.00) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL19299375 0.75 GAA (0.72) GAAKDM4EKMT2AMEN1LMNA
SCHEMBL19294488 0.73 KDM4E (0.72) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL20521849 0.72 SMN1; SMN2 (0.56) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL20522035 0.72 HTT (0.60) KDM4EKMT2AMAPTMEN1HTT
SCHEMBL19294486 0.72 MAPT (1.00) GAAKDM4EKMT2AMAPTMEN1
SCHEMBL11375552 0.72 KMT2A (0.66) GAAKDM4EKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 GAA 416/4885KDM4E 2925/4885KMT2A 2906/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 GAA 416/4885KDM4E 2925/4885KMT2A 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.